美国癌症研究协会（AACR）年会是全球历史悠久、肿瘤领域最具影响力的学术盛会之一。会议关注高质量肿瘤研究及创新研究，聚焦肿瘤领域热点，汇集最前沿进展和科研成果。第115届AACR年会将于美国东部时间2024年4月5日至2024年4月10日在美国加州圣地亚哥举行。当地时间3月5日AACR官网披露摘要标题，【肿瘤资讯】为您精选肺癌领域相关重要临床研究进展。
Clinical Trials Plenary Session
CTPL04-Biomarkers: Quantifying Pharmacodynamic Modulation
摘要号：CT017
摘要标题：FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
Presenter：丹娜法伯癌症研究所 P. A. Jänne
Clinical Trials Minisymposium
CTMS01-Cancer Vaccines: Ready for Prime Time?
摘要号：CT021
摘要标题：Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC
Presenter：荷兰癌症研究所 W. Theelen
CTMS02-Advances in Immunotherapy
摘要号：CT032
摘要标题：Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
Presenter：昭和大学医学部 A. Horiike摘要号：CT034
摘要标题：Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
Presenter：加泰罗尼亚肿瘤研究所 E. Nadal
CTMS03-Novel Agents and Emerging Therapeutic Strategies
摘要号：CT039
摘要标题：Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study
Presenter：罗氏有限公司 F. Mussai摘要号：CT040
摘要标题：First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer
Presenter：加州大学圣地亚哥分校摩尔斯癌症中心 L. Bazhenova
Clinical Trials Poster Session
PO.CT01.04-Phase I Clinical Trials 1
摘要号：CT053/3
摘要标题：Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)
Presenter：延世大学医学院附属世福兰斯医院延世癌症中心 H. Kim摘要号：CT054/4
摘要标题：Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Presenter：延世大学医学院癌症中心 B. Cho摘要号：CT055/5
Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation
Presenter：中国医学科学院肿瘤医院 R. Wan
PO.CT01.01-First-in-Human Phase I Clinical Trials 1
摘要号：CT098/6
摘要标题：Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
Presenter：同济大学附属上海市肺科医院 周彩存（现单位：上海市东方医院）摘要号：CT118/26
摘要标题：Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors
Presenter：江苏奥赛康药业 T. Song摘要号：CT119/27
摘要标题：Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Presenter：华中科技大学同济医学院附属协和医院 董晓荣
PO.CTP01.02-Phase I Clinical Trials in Progress 2
摘要号：CT152/3
摘要标题：FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations
Presenter：德克萨斯大学安德森癌症中心 X. Le
摘要号：CT154/5
摘要标题：Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter：延世大学医学院癌症中心 S. Lim摘要号：CT155/6
摘要标题：Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer
Presenter：再鼎医药 X. Shen摘要号：CT165/16
摘要标题：A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
Presenter：吉林省肿瘤医院 程颖PO.CT01.02-First-in-Human Phase I Clinical Trials 2
摘要号：CT185/13
摘要标题：A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignancies
Presenter：广东省人民医院 吴一龙PO.CT02.01-Phase II Clinical Trials 1
摘要号：CT227/27
摘要标题：Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
Presenter：中山大学肿瘤防治中心 张力
PO.CT03.01-Phase III Clinical Trials
摘要号：CT235/6
摘要标题：RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
Presenter：同济大学附属上海市肺科医院 周彩存（现单位：上海市东方医院）
摘要号：CT238/9
摘要标题：Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
Presenter：阿斯利康 D. Gale摘要号：CT239/10
摘要标题：IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Presenter：中国医学科学院肿瘤医院 王洁
PO.CT02.02-Phase II Clinical Trials 2
摘要号：CT246/5
摘要标题：Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
Presenter：上海交通大学附属胸科医院 李子明摘要号：CT247/6
摘要标题：Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study
Presenter：四川科伦博泰生物医药 X. Jin摘要号：CT248/7
摘要标题：Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial
Presenter：吉林省肿瘤医院 程颖摘要号：CT251/10
摘要标题：Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
Presenter：中国台湾大学医学院附设医院 J.-H. Yang摘要号：CT255/14
摘要标题：AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)
Presenter：四川大学华西医院 Y. Gong
PO.CTP 02.01-Phase II and Phase III Clinical Trials in Progress
摘要号：CT277/7
摘要标题：BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)
Presenter：德克萨斯大学安德森癌症中心 G. Blumenschein, Jr.摘要号：CT280/10
摘要标题：FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)
Presenter：弗吉尼亚癌症专家研究所 A. Spira摘要号：CT281/11
摘要标题：The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)
Presenter：麦吉尔大学蒙特利尔校区 J. D. Spicer摘要号：CT282/12
摘要标题：MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations
Presenter："Regina Elena" 国家癌症研究中心 F. Cappuzzo摘要号：CT283/13
摘要标题：Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%
Presenter：中国台湾大学医学院附设医院 J.-H. Yang摘要号：CT284/14
摘要标题：A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
Presenter：勃林格殷格翰 N. Baktash
排版编辑：肿瘤资讯-Yuno
苏公网安备 32059002004080号
